Lyell Immunopharma, Inc.

NASDAQ:LYEL

Biotechnology

Healthcare
$13.89 +1.20%

+$0.15 today

Market cap
$341.49M
Beta
-0.09
P/E (TTM)
-1.1
EPS (TTM)
-$11.26
52W Low $8.46High $45.00

Volume 0.11M

Average 0.09M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$150.02M

FY 2025 · Annual

Investing Cash Flow

$54.10M

FY 2025 · Annual

-55.8% YoY

Financing Cash Flow

$50.41M

FY 2025 · Annual

+3701.4% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Depreciation & Amortization13.62M16.47M20.25M19.63M11.54M
Deferred Income Tax39.51M0000
Stock-Based Compensation62.2M047.08M33.14M41.83M
Change in Working Capital4.02M(82.02M)3.42M(3.12M)(9.89M)
Accounts Receivables00000
Inventory00000
Accounts Payables91K667K1.46M(3.23M)(2.34M)
Other Working Capital3.92M(82.68M)1.96M114K(7.56M)
Other Non-Cash Items4.62M79.11M183K130.95M80.95M
Operating Cash Flow(126.25M)(169.56M)(163.69M)(162.39M)(150.02M)
Capital Expenditures(65.5M)(24.28M)(2.69M)(464K)(780K)
Acquisitions (Net)673.47M00(31.35M)(41.2M)
Purchases of Investments(673.47M)(406.32M)(476.88M)(394.71M)(259.71M)
Sales of Investments617.4M419.05M663.61M548.94M374.68M
Other Investing Activities(673.47M)000(18.9M)
Investing Cash Flow(121.57M)(11.54M)184.05M122.42M54.1M
Debt Repayment00000
Common Stock Issued391.8M11.1M2.2M1.4M50.41M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities9.44M(461K)(457K)(76K)(1K)
Financing Cash Flow401.24M10.64M1.74M1.33M50.41M
Effect of Forex Changes0186K(4K)00
Net Change in Cash153.42M(170.27M)22.09M(38.64M)(45.52M)
Free Cash Flow(191.75M)(193.83M)(166.38M)(162.86M)(150.8M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$274.4M
+ D&A$11.5M
+ Stock-Based Comp$41.8M
+ Deferred Tax$0
- Working Capital-$9.9M
+ Other Non-Cash$81.0M
= Operating Cash Flow-$150.0M
- Capex-$780.0K
= Free Cash Flow-$150.8M

Analysis

FY2025 free cash flow is -$150.8M. FCF conversion is 54.9% of net income. Operating cash flow was -$150.0M, with capex of -$780.0K. The largest bridge item is Other Non-Cash at $81.0M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
S-3S-3 filingNov 13, 2026
4Statement of changes in beneficial ownershipNov 12, 2026
4Statement of changes in beneficial ownershipNov 12, 2026
4Statement of changes in beneficial ownershipNov 12, 2026
4Statement of changes in beneficial ownershipNov 12, 2026

Does LYEL generate free cash flow?

Lyell Immunopharma, Inc. (LYEL) generated -$150.80M of free cash flow in fiscal 2025.

How much operating cash flow does LYEL produce?

Operating cash flow was -$150.02M, before capital expenditures of $780,000.00.